CASI Pharmaceuticals Inc is a holding company principally engaged in developing and commercializing innovative therapeutics and pharmaceutical products. The Companyâ€™s main business is engaged in acquiring, developing and commercializing products that augment its hematology oncology, autoimmune and organ transplant rejection therapeutic area focus as well as other unmet medical need. The Companyâ€™s main products include EVOMELA (Melphalan for Injection), FOLOTYN (Pralatrexate), CNCT19, BI-1206, CB-5339, CID-103, Thiotepa and others. The Company mainly conducts its business in the domestic market.

Employees

Sector

Pharmaceuticals

More about the company

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Jun. 02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
May. 15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	3.02M 2.64M 2.43M 2.26M 4.29M 288M 4.35M 29.12M 11.32M 141M 11.33M 11.09M 487M	P/E 2026 *	-0.1x	P/E 2027 *	-0.11x
Enterprise Value	3.02M 2.64M 2.43M 2.26M 4.29M 288M 4.35M 29.12M 11.32M 141M 11.33M 11.09M 487M	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	53.62%	Yield 2026 *	-	Yield 2027 *	-

Jun. 02	CASI Pharmaceuticals, Inc. Announces Resignation of Barbara Krebs-Pohl as Director, Effective May 31, 2026	CI
May. 15	CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 14	CASI Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	CI
Apr. 20	CASI Pharmaceuticals, Inc. announced that it has received $20 million in funding from ETP Global III Fund LP	CI
Apr. 20	CASI Pharmaceuticals, Inc. Announces Termination of Dr. Alexander A. Zukiwski, MD as Global Chief Medical Officer, Effective April 20, 2026	CI
Mar. 03	CASI Pharmaceuticals, Inc. Announces CEO Changes	CI
Mar. 03	Casi Pharmaceuticals, Inc. Announces Resignation of Director David Cory, Effective March 31, 2026	CI

Manager	Title	Age	Since
David Cory CEO	Chief Executive Officer	62	2025-07-20
Kun Qian DFI	Director of Finance/CFO	44	2025-05-15
Chun Hua Wang COO	Chief Operating Officer	54	2016-12-31

Director	Title	Age	Since
Yue Wu BRD	Director/Board Member	62	2013-03-31
Zhen Bo Su BRD	Director/Board Member	50	2023-03-20
Thomas Folinsbee BRD	Director/Board Member	59	2023-03-20

ENTREMED Stock Nasdaq

Stocks

Pharmaceuticals

Valuation: ENTREMED

Latest news : ENTREMED

Press Releases: ENTREMED

Managers and Directors: ENTREMED

Other Pharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	+1.86%	+0.48%	+55.50%	+163.08%	1,082B
JOHNSON & JOHNSON	+3.57%	+3.29%	+68.60%	+61.03%	633B
ABBVIE INC.	+3.99%	+3.05%	+37.93%	+93.37%	461B
ROCHE HOLDING AG	+3.86%	+1.64%	+32.57%	+24.89%	338B
ASTRAZENECA PLC	-0.56%	+0.96%	+41.67%	+39.35%	299B
NOVARTIS AG	-0.08%	+1.30%	+32.15%	+44.48%	291B
NOVO NORDISK A/S	-1.54%	+2.81%	-25.35%	-39.61%	222B
AMGEN INC.	+3.55%	+4.41%	+25.45%	+66.28%	202B
GILEAD SCIENCES, INC.	+4.21%	+2.65%	+17.47%	+71.11%	163B
Average	+2.10%	+4.58%	+31.78%	+58.22%	410.27B
Weighted average by Cap.	+2.25%	+5.53%	+42.31%	+83.31%

	2026 *	2027 *
Net sales	-	-
Net income	-24.73M -21.62M -19.86M -18.52M -35.12M -2.35B -35.65M -238M -92.71M -1.16B -92.81M -90.82M -3.99B	-26.51M -23.18M -21.3M -19.85M -37.65M -2.52B -38.22M -256M -99.4M -1.24B -99.51M -97.37M -4.28B
Net Debt	-	-

End-of-day quote Nasdaq Other stock markets
- ^USD	-